National Bank of Canada
ABCL icon

National Bank of Canada’s AbCellera Biologics ABCL Stock Holding History

National Bank of Canada’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$393K Buy
+500
New +$2.44K ﹤0.01% 1502
2024
Q3 		– Sell
-299
Closed -$83.1K – 2728
2024
Q2 		$83.1K Hold
299
– – ﹤0.01% 1538
2024
Q1 		$115K Buy
+299
New +$1.53K ﹤0.01% 1519

Other funds holding ABCL

TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CMF
Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.11B AUM 38.73% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
DRP
Decker Retirement Planning Levi, Utah $294M AUM 97.44% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return
CFG
Citizens Financial Group Providence, Rhode Island $8.3B AUM 27.66% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

National Bank of Canada's ABCL Position: Q2 2026 in Review

National Bank of Canada increased its AbCellera Biologics (ABCL) stake by 88,415% in Q2 2026, buying an estimated $6.02M and bringing the position to 1,233,014 shares worth $9.68M. The position accounts for 0.01% of the portfolio, ranked #754.

National Bank of Canada first reported a position in ABCL in Q4 2021 and has held it in 18 quarters since. 65 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • National Bank of Canada held 1,233,014 shares of AbCellera Biologics worth $9.68M as of Q2 2026.
  • National Bank of Canada bought 1,231,621 AbCellera Biologics shares in Q2 2026, an estimated $6.02M.
  • AbCellera Biologics made up 0.01% of National Bank of Canada's portfolio in Q2 2026, its #754 holding.
  • National Bank of Canada first reported a position in AbCellera Biologics in Q4 2021 and has held it in 18 quarters since.
  • 65 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.